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Abstract
Background: The Exercise Intensity Trial (EXcITe) is a randomized trial to compare the efficacy of supervised
moderate-intensity aerobic training to moderate to high-intensity aerobic training, relative to attention control, on
aerobic capacity, physiologic mechanisms, patient-reported outcomes, and biomarkers in women with operable
breast cancer following the completion of definitive adjuvant therapy.
Methods/Design: Using a single-center, randomized design, 174 postmenopausal women (58 patients/study arm)
with histologically confirmed, operable breast cancer presenting to Duke University Medical Center (DUMC) will be
enrolled in this trial following completion of primary therapy (including surgery, radiation therapy, and
chemotherapy). After baseline assessments, eligible participants will be randomized to one of two supervised
aerobic training interventions (moderate-intensity or moderate/high-intensity aerobic training) or an attention-
control group (progressive stretching). The aerobic training interventions will include 150 mins.wk-1 of supervised
treadmill walking per week at an intensity of 60%-70% (moderate-intensity) or 60% to 100% (moderate to high-
intensity) of the individually determined peak oxygen consumption (VO2peak) between 20-45 minutes/session for
16 weeks. The progressive stretching program will be consistent with the exercise interventions in terms of
program length (16 weeks), social interaction (participants will receive one-on-one instruction), and duration (20-45
mins/session). The primary study endpoint is VO2peak, as measured by an incremental cardiopulmonary exercise
test. Secondary endpoints include physiologic determinants that govern VO2peak, patient-reported outcomes, and
biomarkers associated with breast cancer recurrence/mortality. All endpoints will be assessed at baseline and after
the intervention (16 weeks).
Discussion: EXCITE is designed to investigate the intensity of aerobic training required to induce optimal
improvements in VO2peak and other pertinent outcomes in women who have completed definitive adjuvant
therapy for operable breast cancer. Overall, this trial will inform and refine exercise guidelines to optimize recovery
in breast and other cancer survivors following the completion of primary cytotoxic therapy.
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Background
Cardiorespiratory fitness is one of the most important
indicators of health and longevity in humans [1,2]. The
efficiency of mammals to transport O2 from the atmo-
sphere to the muscle mitochondria determines an indi-
vidual’s cardiorespiratory fitness [3]. Maximal or peak
oxygen consumption (VO2peak) provides the gold stan-
dard measurement of cardiorespiratory fitness and is
strongly and inversely related to risk of death [4-8].
The importance of cardiorespiratory fitness for women
following a breast cancer diagnosis has received limited
attention [9]. However, over the past decade, there has
been increased recognition and acceptance of the impor-
tance of therapy late effects (e.g., cardiovascular disease,
type 2 diabetes, fatigue, deconditioning, etc.) as a major
but underappreciated area in breast cancer management
[10]. Emerging research evidence indicates that poor
cardiorespiratory fitness may be of central importance
for certain adverse late effects including impaired left
ventricular ejection fraction, elevated cardiovascular dis-
ease (CVD) risk profile, poor quality of life, and fatigue
following the completion of adjuvant therapy for oper-
able breast cancer[11-13]. Further, recent landmark
observational studies report that regular self-reported
physical activity (e.g., brisk walking, ≥ 30 min.d-1, 5 d.
wk-1), a major determinant of cardiorespiratory fitness,
is associated with 30% to 50% reductions in breast can-
cer-specific mortality and all-cause mortality following
the completion of adjuvant therapy[14,15].
Despite its importance, women with breast cancer
have markedly reduced cardiorespiratory fitness. In a
series of studies, we observed that cardiorespiratory fit-
ness was approximately 30% below that of age-matched
sedentary healthy women up to three years following
the completion of adjuvant therapy[11,12,16]. The pre-
cise causes of poor cardiorespiratory fitness are not
known but likely are a consequence of direct cytotoxic
therapy-associated injury to the cardiovascular system
(e.g., impairments in the organ components that govern
VO2peak) together with lifestyle perturbations (e.g.,
deconditioning and weight gain) that we have termed
the ‘multiple hit’ hypothesis[9].
A growing number of research groups have investi-
gated the efficacy of supervised exercise training inter-
ventions (aerobic, resistance, or combination training) to
counteract therapy-induced poor cardiorespiratory fit-
ness both during and following the completion of adju-
vant therapy. Overall, the current literature base
indicates that supervised exercise training is a safe and
feasible adjunctive therapy associated with significant
improvements in objective measures of cardiorespiratory
fitness as well as a broad range of patient-reported out-
comes (PROs)[17]. Preliminary data also indicate that
aerobic training may cause favorable improvements in
circulating metabolic hormone concentrations in women
with operable breast cancer following the completion of
adjuvant therapy[18,19].
Although much progress has been made over the
past 20 years, the format and intensity of exercise
required to induce optimal improvements in cardiore-
spiratory fitness and other pertinent outcomes in
women with breast cancer has not been investigated.
The American College of Sports Medicine (ACSM)
convened a panel of experts to review the available evi-
dence supporting exercise prescription guidelines for
cancer survivors[20]. The panel concluded that cancer
survivors follow the 2008 Physical Activity Guidelines
for Americans (≥ 150 mins.wk-1 of moderate-intensity,
or ≥ 75 mins.wk-1 vigorous-intensity aerobic exercise
or an equivalent combination of moderate- and vigor-
ous intensity aerobic exercise) for cancer survivors, yet
few studies have tested this empiric prescription in a
formal randomized controlled trial. Furthermore,
recent trials in other diseases besides cancer report
that high-intensity exercise (≥ 70% of baseline VO2peak)
is safe and feasible and associated with superior
improvements in VO2peak and related endpoints rela-
tive to moderate-intensity training in patients with left
ventricular dysfunction, heart failure, and metabolic
syndrome[21-27]. To our knowledge, the efficacy of
high-intensity exercise training has not been investi-
gated in women with operable breast cancer.
Against this background, we designed the EXCITE
trial, a randomized trial comparing the effects of super-
vised moderate-intensity to high-intensity aerobic train-
ing in women with operable breast cancer following the
completion of primary adjuvant therapy. The primary
aims are to: (1) compare the effects of high-intensity to
moderate-intensity aerobic training, relative to atten-
tion-control, on VO2peak, (2) determine the effects on
the physiological mechanisms that govern VO2peak (mea-
surements of the heart-lung-skeletal muscle axis), and
(3) to compare the effects on PROs. A secondary aim is
to determine the effects on biomarkers associated with
breast cancer recurrence that may underlie the exercise
- breast cancer prognosis relationship (i.e., systemic
metabolic hormones and cytokines/angiogenic factors).
Herein we report details of the study design.
Methods/Design
Participants and Setting
In EXCITE, we will recruit and randomize 174 postme-
nopausal women (58 subjects/study arm) with histologi-
cally confirmed operable breast cancer (tumors positive
or negative for estrogen receptors and progesterone
receptors, and HER-2) following completion of primary
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therapy presenting at Duke University Medical Center
(DUMC) for routine follow-up care will be eligible for
this study. The DUMC institutional review board
approved the study and written informed consent will
be obtained from all participants prior to initiation of
any study procedures. Additional inclusion and exclu-
sion criteria are described in additional file 1.
Procedures
The study flow is presented in Figure 1. Using a three-
arm, randomized design, potential subjects will be iden-
tified and screened for eligibility by the study research
coordinators via medical record review of patients
scheduled to attend a ‘follow-up’ consultation at the
Duke Breast Cancer Survivorship Clinic as per standard
of care or following direct referral from their oncologist.
Following primary attending oncologist approval, poten-
tial eligible subjects will be provided with a thorough
review of the study and asked if they are willing to parti-
cipate. After obtaining written consent, all participants
will complete the following assessments in order of pre-
sentation: (1) fasting blood draw and oral glucose toler-
ance test, (2) peripheral vascular endothelial function,
(3) spirometry and cardiopulmonary exercise test, and
(4) echocardiogram at rest and during exercise and (5)
PRO survey forms. On the following day, patients will
undergo a tissue biopsy of the vastus lateralis. Partici-
pants will be asked to adhere to a water-only fast for 8
hours prior to testing on both days. All baseline assess-
ments will be repeated at the end of the intervention
(16 weeks). To maximize internal validity, study person-
nel, time of the day, equipment, and assessment order
and timing will be the same at baseline and
postintervention.
Group Allocation (Randomization)
Following the successful completion of baseline assess-
ments, participants will be randomly allocated, on an
individual basis, to one of the two aerobic training
interventions (high-intensity or moderate-intensity
training) or an attention-control group (progressive
stretching). Randomized participants will remain in the
same group for the entire duration of the intervention.
To ensure randomized groups are similar at baseline,
patient randomization will be stratified based on prior
treatment with chemotherapy and current treatment
with endocrine therapy. A computer-generated list of
random treatment assignments will be created by the
trial statistician in sequentially numbered, opaque,
sealed envelopes. A permuted block design with alloca-
tion weight of 1:1:1 will be used to generate the treat-
ment assignments.
Potentially eligible patients attending routine ‘follow-up’ consultation at 
the Duke Breast Cancer Survivorship Clinic 
Interested Participants Scheduled for Baseline Assessments 
(Assessment #1)
Arm 1
Moderate-Intensity Aerobic 
Training 
Arm 2
Moderate to High-Intensity 
Aerobic Training 
Arm 3
Attention-Control 
(Progressive Stretching) 
Assessment #2 (16 weeks post randomization)
Randomization, n=58/Group (stratified by prior chemotherapy & current 
endocrine therapy) 
Figure 1 Study Flow.
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Blinding and Masking
Study personnel conducting assessments at baseline and
follow-up will be blinded to treatment assignment. Only
the trial statistician and the data safety monitoring com-
mittee will have access to unblinded data, but none will
have any direct contact with study participants or study
personnel.
Exercise Training Protocols (General Considerations)
The aerobic training interventions will include 150 mins.
wk-1 of supervised exercise sessions per week at an
intensity of 60%-75% (moderate-intensity) or 60% to
100% (high-intensity) of the individually determined
VO2peak between 20-45 min/session for 16 weeks. To
achieve 150 mins.wk-1 of supervised exercise per week,
participants will be asked to exercise 4 times over a
seven day period. Both aerobic training interventions are
designed such that participants begin exercising at a low
intensity (~50%-60% VO2peak) for shorter durations
(~20-25 min/session) that is subsequently increased to a
moderate (60%-70% VO2peak) or moderate-high intensity
(60% to 100% VO2peak) for 150 mins.wk
-1 by week 4 of
the program. All intervention sessions, including atten-
tion-control stretching, will be performed in a super-
vised setting with one-on-one supervision by a certified
exercise physiologist for same duration per session to
ensure that the only difference between sessions is the
intensity of aerobic training. We believe that supervised
sessions are critical to maximize adherence (>80% of
planned sessions) to the intervention both in terms of
attendance and adherence to the prescription. Optimiz-
ing adherence is critical to ensure a robust test of aero-
bic training and stretching (attention-control) efficacy.
Study Arm 1
Moderate-Intensity: Moderate-intensity aerobic training
will be prescribed based on the ACS guidelines[20]. The
moderate-intensity aerobic training intervention will
work toward the target of four treadmill walking ses-
sions/week at 60%-70% of VO2peak for 150 mins.wk
-1.
Treadmill walking was chosen because it is the preferred
mode of exercise training for breast cancer patients[28].
In the introductory phase of the program (Weeks 1-4),
the frequency, duration, and intensity of aerobic training
will be progressively increased from an initial prescrip-
tion of 3 session/wk for ~20 mins/session at ~60% of
VO2peak to the ultimate goal of this prescription (150
mins.wk-1 at 60%-70% VO2peak) at the end of week 4.
The goal of these sessions will be to introduce aerobic
training, including warm-up, heart rate and rate of per-
ceived exertion monitoring, as well as cycling pace and
proper form. Given that study participants will be
sedentary, we believe that it is first important to intro-
duce aerobic training and establish a cardiovascular base
prior to introducing higher intensity aerobic training.
Once the desired prescription has been obtained, in
Weeks 5-16, patients will perform all sessions at the
same intensity and duration for the remainder of the
study consistent with the ACSM guidelines[20].
Study Arm 2
Moderate to High-Intensity Aerobic Training: The goal
of this intervention is to improve VO2peak. As in Arm 1,
all aerobic training sessions will be performed on a
motorized treadmill. The moderate to high-intensity
aerobic training intervention will target delivery of four
treadmill walking sessions/week at 60%-100% of VO2peak
for 150 mins.wk-1.
As in Arm 1, In the introductory phase of the pro-
gram (Weeks 1-4), the frequency, duration, and intensity
of aerobic training will be progressively increased from
an initial prescription of 3 session/wk for ~20 mins/ses-
sion at ~60% of VO2peak to the ultimate goal of this pre-
scription (150 mins.wk-1 at 60%-100% VO2peak) at the
end of week 4. In Weeks 5 to 8 (intermediate phase),
the goal will be to introduce higher intensity aerobic
training. Specifically, exercise intensity will range
between ~60%-70% VO2peak for two sessions per week;
in the remaining two sessions, exercise intensity will be
set at ventilatory threshold (~75% VO2peak). In weeks 9
to 16 (optimization phase), similar to the intermediate
phase, participants will be asked to perform 4 aerobic
sessions per week; 3 sessions will be performed at
~60%-80% VO2peak, and one interval workout. Interval
workouts will consist of 2 min at the workload asso-
ciated with peak VO2 (100% of VO2peak) followed by 2-
4 min of active recovery for 4-6 intervals. At week 8,
participants will undergo a mid-point cardiopulmonary
exercise test to re-assess VO2peak. On the basis of these
results, the exercise prescription will be adjusted to
ensure progressive improvements in VO2peak across the
entire intervention.
Study Arm 3
Attention Control: Subjects assigned to the attention-
control group will perform a supervised progressive
stretching program that is matched to the exercise inter-
ventions in terms of program length 16 weeks),
frequency [social interaction (participants will receive
one-on-one instruction)], and duration (20-45 min per
session). The progressive stretching program will be pre-
scribed according the ASCM flexibility guidelines for
older adults and aimed at increasing whole-body flexibil-
ity[29]. Stretching will be performed supine on stretch-
ing mats (no machines). Patients will be progressively
trained to perform eight stretching exercises alternating
between lower and upper body muscle groups.
Subject Retention/Adherence Considerations To opti-
mize subject retention and adherence in all three experi-
mental conditions several strategies will be employed
including: (1) individualized attention at the intervention
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sessions (in all experimental conditions), telephone calls
following missed sessions, individuals meetings to out-
line goals and providing feedback on study progress, (2)
participants will be allowed to make-up missed sessions
within the 16-week study period, (3) participants will be
allowed to schedule supervised interventions sessions at
anytime from 7 AM to 7 PM, and (4) the PI and exer-
cise physiologists will also meet on a weekly basis to
review each participant’s adherence with weekly inter-
vention exercise prescription.
Study Endpoints and Assessments
Table 1 outlines the study assessment schedule while a
brief description of study endpoints and endpoint
assessments including sub-studies is provided in addi-
tional file 2.
Primary Endpoint
To determine VO2peak, an incremental treadmill test
(modified Balke protocol) with 12-lead ECG monitoring
(Mac® 5000, GE Healthcare) will be performed by
ACSM-certified exercise physiologists blinded to the
patient’s randomization group. Expired gases will be
analyzed continuously by a metabolic measurement sys-
tem (ParvoMedics TrueOne® 2400, Sandy, UT). After
stable resting metabolic values have been achieved
(including blood pressure and heart rate), subjects will
begin walking at pace selected in the warm-up as a
comfortable but brisk pace (~2.5-4.0 mph) at 0% grade
for 2 minutes. Grade will be increased every 2 minutes
until ventilatory threshold and then every minute until
exhaustion or a symptom-limitation. During exercise
oxyhemoglobin saturation will be monitored continu-
ously using pulse oximetry (BCI, Hand-Held Pulse Oxi-
meter, Waukesha, WN) while blood pressure will be
measured every two minutes. Rating of perceived
exertion will be evaluated at the end of each workload
using the modified Borg Scale. Finally, significant learn-
ing effects are often observed in patient populations not
familiar with CPET procedures. Thus, the CPET will be
repeated prior to randomization to ensure the most
accurate measurement of VO2peak and optimal aerobic
training prescription.
Secondary Endpoints
Physiological Determinants of VO2peak will include pul-
monary function, cardiovascular O2 delivery, peripheral
artery endothelial function, and skeletal muscle function.
Pulmonary Function will be determined using stan-
dard spirometry. All measures will be performed in a
sitting position according to the American Thoracic
Society guidelines[30].
Cardiovascular O2 Delivery is comprised of four end-
points: (1) Cardiac Output. Left ventricular volumes and
blood flow velocities will be performed with a commer-
cially available ultrasound system (GE vivid-q BT10 Sys-
tem). Apical two- and four- chamber views will be
assessed at rest and exercise to determine left ventricu-
lar end-diastolic volume and end-systolic volume by
modified Simpson’s rule[31,32]. Stroke volume will be
calculated as end-diastolic volume minus end-systolic
volume, which will be confirmed by measurement of left
ventricular outflow tract area and the aortic flow velo-
city integral. Cardiac output will be calculated as stroke
volume multiplied by heart rate. Blood pressure will be
measured by auscultatory sphygmomanometry during
exercise to determine mean arterial pressure. Systemic
vascular resistance will be calculated as mean arterial
pressure divided by cardiac output; (2) Hemoglobin (Hb)
Concentration (O2 carrying capacity of blood) will be
assessed via a venous blood draw according to standard
guidelines, (3) Arterial O2 Saturation will be assessed at
Table 1 Study Assessment Schedule
Baseline Post-Intervention (16 weeks)
Assessment Screening Day 0 Day 1 Day 2 Day 3-5 Day 112 Day 113
Chart Review x
Patient Approached x
Informed Consent x
Outcome Assessments
Patient-reported outcomes x
Blood draw x x
Oral Glucose Test x x
Endothelial Function x x
VO2peak x x
Echocardiogram x x
Muscle biopsy x x
Repeat VO2peak x
Randomization x
Intervention initiation x
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rest and continuously during exercise using pulse oxi-
metry (Biox 3700, Ohmeda Medical, Boulder, CO),
which provides the most accurate noninvasive assess-
ment of blood arterial O2 saturation levels.
Brachial Artery Endothelial Function will be assessed
using a commercially -available high-resolution ultra-
sound and a 7.5 MHz linear array transducer (HP Sonos
2000). Brachial artery assessments (a surrogate of sys-
temic nitric oxide-bioavailability) will be obtained in
longitudinal view, approximately 4 cm proximal to the
olecranon process, in the anterior/medial plane, during
the five minutes of forearm occlusion, and following
cuff release (hyperemia) as previously described[33].
Skeletal Muscle Studies: Muscle biopsies and hand-
ling of tissue Muscle will be obtained with the percuta-
neous needle biopsy technique (Bergstrom needles,
DePuy Co., Inc., Warsaw, IN). We have consistently
obtained tissue sample of 150-200 mg with a triple pass
from a single incision, and we have demonstrated that
this amount of tissue is sufficient for analyzing muscle
fiber composition, capillarity, and metabolic enzymes
[34].
Capillarity and histochemistry The arrangement of
capillaries in skeletal muscle typically is measured as
capillaries2mm-2 (capillary density). Capillary density is
dependent on the size of the muscle fibers: larger fibers
have lower capillary density. Thus, it is important to
also express the extent of capillarization in terms of the
capillary/fiber ratio, which is relatively independent of
fiber area. Capillary counting will be performed as pre-
viously described[34]. For determination of fiber type,
serial sections will be stained for myosin ATPase after
preincubation at pH of 4.37, 4.6, and 10.4, to identify
types I, IIa, and IIb muscle fibers[35].
Enzymology The mitochondrial enzymes oxoglycerate
dehydrogenase, citrate synthase, and 3-hydroxy-CoA-
dehydrogenase will be determined. The activities of the
glycolytic enzymes phosphofructokinase, aldolase, and
lactate dehydrogenase will be measured as well as pyru-
vate dehydrogenase (total plus relative activity) as
described previously[35].
Patient Reported Outcomes will include quality of life
(QOL), fatigue, and depression. QOL will be assessed
using the Functional Assessment of Cancer Therapy -
Breast (FACT-B) scale developed for the assessment of
patient symptoms and QOL in breast cancer patients
[36]. Fatigue will be assessed using the 13-item FACT-
fatigue scale for the assessment of fatigue in cancer
patients[37]. Finally, depression will be assessed using
the Center for Epidemiologic Studies Depression scale
(CES-D)[38].
Biologic Mechanisms Whole-Body Metabolic Control
will consist of: Insulin-Sensitivity assessed using a stan-
dard oral glucose tolerance test analysis after an
overnight fast. After sampling for baseline glucose and
insulin, subject will be given a 296-mL glucose drink
(Azer Scientific, Morgantown, PA) containing 75 g of
glucose and samples drawn at 30, 60, 90, and 120 min-
utes after drink consumption. Glycosylated Hemoglobin
(HbA1C) and fasting insulin will be measured using a
CLIA approved clinical laboratory. Systemic cytokines/
angiogenic factors will be evaluated and characterized in
fasted blood prepared for multiplex assay analysis using
Luminex 100/200 System (Luminex Corp, Austin, Tx)
as previously described[39,40].
Tracking and Monitoring of Adverse Events
Adverse events will be tracked and monitored using the
following methods: (1) during intervention sessions, all
patients will receive one-on-one supervision and all
adverse events (e.g., knee pain, back pain) will be
recorded on the patient case report form (CRF). In addi-
tion, heart rate, blood pressure, and O2 saturation will
be recorded prior to, during, and following every inter-
vention session, (2) at the beginning of each week, the
exercise physiologist will spend the first 10 minutes of
every session discussing any potential negative side-
effects of the intervention assignment and any injuries
that may have occurred; (3) during the program, all
study participants will provide a blood sample every 4
weeks. A Complete Blood Count will conducted on each
sample to monitor changes in white blood cell and
white blood cell differential (neutrophils, lymphocytes,
and monocytes) to provide insight into the effects of
exercise on immune function, and (4) every six months
a meeting of all investigators will be scheduled to review
and discuss all reported non-serious and serious adverse
events for early identification of negative issues and
development of solutions. All serious adverse events will
be immediately reported to DUMC IRB and immediately
circulated to all study investigators for appropriate dis-
cussion, and early stopping rules in response to a differ-
ential higher frequency of adverse events in a particular
study group will be enforced.
Statistical Considerations
Sample Size Calculation
This randomized phase III trial will accrue 174 patients
with operable breast cancer over an accrual period of ~48
months. The power of both an overall F-test comparison
for the study’s primary outcome variable, VO2peak, among
experimental groups is considered as part of power calcu-
lations, as well as two primary pair wise comparisons (i.e.,
moderate-intensity versus moderate to high-intensity
training; moderate to high-intensity training versus atten-
tion-control). The power of pairwise comparisons is com-
puted with adjustment for multiple comparisons using a
Bonferroni correction factor (a = 0.05/2 = 0.025). These
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calculations assume a lost-to-follow-up rate of 15% (8 in
each group or 24 in total). Thus, it is anticipated that 150
will provide evaluable data at follow-up (16 weeks). The
power estimates were calculated using the following
observed/expected change in VO2peak from baseline to 16
weeks: moderate-intensity -training: +1.5 mL.kg.-1min-1;
moderate to high-intensity training: +4.0 mL.kg.-1min-1;
and attention-control: 0.0 mL.kg.-1min-1. Power estimates
assume the SD for the change in VO2peak to be equal for
all these groups (4.0 mL.kg.-1min-1) obtained from our
prior work among post therapy breast cancer patients
[11,12]. With 150 patients having evaluable post-interven-
tion follow-up, there is >99% power to detect the noted
difference among the three experimental groups with an
F-test conducted with two degree of freedom. With 50
patients per group having evaluable post-intervention fol-
low-up, there is 80% power to detect a 2.5 mL.kg.-1min-1
difference in VO2peak between the aerobic training inter-
ventions; and >99% power to detect a 4.0 mL.kg.-1min-1
difference in VO2peak between moderate to high-intensity
aerobic training and attention-control using a two-sided
alpha of 0.025 If analyses included all 174 patients (i.e. 58
per group), these pair-wise comparisons will have 86% and
>99% power, respectively.
Analytic Plan
The principal analysis of the primary outcome will
employ the intention-to-treat (ITT) approach. The ITT
analysis will include all randomized participants in their
randomly assigned group. The intervention group
assignment will not be altered based on the participant’s
adherence to the randomly allocated study arm. The pri-
mary analysis will use a multiple regression model to
test for differences among and between the study arms
in VO2peak from baseline to the post intervention assess-
ment (16 weeks). Specifically, two comparisons will be
conducted: (1) moderate-intensity training versus atten-
tion control, and (2) moderate to high-intensity training
versus attention control. The outcome variable in the
basic regression model is change in VO2peak; whereas
predictors include study group, baseline VO2peak, as well
as the interaction. The regression model will allow con-
trolling for the baseline value of the study endpoints
and other confounding variables that may impact
change in VO2peak (e.g., self-reported exercise history,
age, prior treatment, exercise adherence). Finally, regres-
sion analyses will initially focus on participants that
complete a follow-up assessment. Missing follow-up
assessments will be imputed under different assump-
tions and used in additional analyses to assess the sensi-
tivity of inferences to missing data. Multiple regression
models will also be used to compare study arms relative
to the change in physiological mediators (e.g. cardiac
function, peripheral vascular endothelial function, and
skeletal muscle oxidative capacity) of the aerobic
training - VO2peak relationship. Following the guiding
principles of Baron and Kenny, analyses will be con-
ducted that investigate whether physiological variables,
such as pulmonary function, cardiac output, and skeletal
muscle function, mediate the effect of exercise training
on VO2peak.
Discussion
Methodological Considerations
Several methodological issues were considered when
designing EXCITE. Of these, the most paramount were
issues surrounding the feasibility and tolerability of mod-
erate to high-intensity aerobic training in women with a
history of breast cancer. To our knowledge, all prior stu-
dies in breast cancer patients have investigated the effects
of exercise training prescribed at a moderate-intensity
(i.e., ~50% to ~70% baseline cardiorespiratory fitness)
either during or following adjuvant therapy. There is a
prevailing opinion in the oncology literature that high-
intensity exercise training is not feasible or even contra-
indicated for individuals with a history of cancer;[41] this
is likely based on the potential immunosuppressive
effects of exercise training conducted ≥ 75% of VO2peak.
However, evidence to support this notion is lacking. In
contrast, recent trials in non-cancer clinical populations
report that high-intensity exercise (≥ 70% of baseline
VO2peak) is safe and well-tolerated approach associated
with superior improvements in VO2peak and related end-
points, relative to moderate-intensity training[21-27].
Furthermore, two pilot studies by our group found that
high-intensity aerobic training was feasible and safe
among patients with non-small cell lung cancer[42,43].
Taken together, there exists sufficient evidence to investi-
gate the efficacy of high-intensity aerobic training in
women following completion of definitive adjuvant ther-
apy for operable breast cancer. Given the novelty of this
approach in the oncology setting, we will employ several
methods to carefully monitor and assess adverse events
in this trial as described earlier in the paper.
A second consideration is that adherence to super-
vised aerobic training 4 d.wk-1 may be over burdensome
for a proportion of women with breast cancer. The vast
majority of prior exercise oncology trials have investi-
gated the feasibility and efficacy of exercise training con-
ducted 3 d.wk-1, which is clearly more feasible, but the
goal of this study is to test the effects of ≥ 150 min of
exercise per week, consistent with the ACSM recom-
mendations[20]. Similarly, we acknowledge that while
incorporating home-based sessions in the prescription
may increase adherence, we believe that it critically
important to monitor all exercise sessions to optimize
safety and ensure that all sessions were performed at
the correct intensity and ensure that the duration of
each exercise session is equal between all groups.
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Conclusions
It is becoming increasingly apparent that cardiorespira-
tory fitness is a parameter of critical importance follow-
ing a breast cancer diagnosis. However, as a result of
the direct and indirect deleterious effects of anticancer
therapy (the multiple-hit hypothesis), cardiorespiratory
fitness is markedly reduced in breast cancer patients
[3,9]. Although the long-term clinical implications are
not known, such injury may increase susceptibility to
competing causes of morbidity, poor quality of life, and
even premature mortality
EXCITE was designed to investigate the intensity of
aerobic training required to induce optimal improve-
ments in VO2peak and other pertinent outcomes in
women who have completed definitive adjuvant ther-
apy for operable breast cancer. To the best of our
knowledge, EXCITE is the first trial to compare the
efficacy of different intensities of aerobic training and
the first to examine changes in the physiologic
mechanisms that govern cardiorespiratory fitness in
breast cancer patients. The fundamental rationale for
this study is that investigating the level and format of
aerobic training that produces optimal improvements
in VO2peak and other related clinical endpoints will
inform evidence-based exercise guidelines for breast
and other cancer populations. Insight into the changes
in physiological determinants that underlie the aerobic
training - VO2peak relationship will further refine exer-
cise guidelines and inform novel combination
approaches to maximize health and longevity in this
population, as well as elucidating the mechanisms of
benefit. Finally, the addition of correlative science stu-
dies that examine the effects of aerobic training on
changes in biomarkers associated with recurrence/
prognosis will inform mechanistically-driven clinical
trials of exercise on surrogate markers of survival in
breast cancer patients[41].
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